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Expression of the feline immunodeficiency virus (FIV) accessory protein OrfA (or Orf2) is critical for efficient viral replication in lymphocytes,
both in vitro and in vivo. OrfA has been reported to exhibit functions in common with the human immunodeficiency virus (HIV) and simian
immunodeficiency virus (SIV) accessory proteins Vpr and Tat, although the function of OrfA has not been fully explained. Here, we use microarray
analysis to characterize how OrfA modulates the gene expression profile of T-lymphocytes. The primary IL-2-dependent T-cell line 104-C1 was
transduced to express OrfA. Functional expression of OrfAwas demonstrated by trans complementation of the OrfA-defective clone, FIV-34TF10.
OrfA-expressing cells had a slightly reduced cell proliferation rate but did not exhibit any significant alteration in cell cycle distribution. Reverse-
transcribed RNA from cells expressing green fluorescent protein (GFP) or GFP + OrfAwere hybridized to Affymetrix HU133 Plus 2.0 microarray
chips representing more than 47,000 genome-wide transcripts. By using two statistical approaches, 461 (Rank Products) and 277 (ANOVA) genes
were identified as modulated by OrfA expression. The functional relevance of the differentially expressed genes was explored by Ingenuity Pathway
Analysis. The analyses revealed alterations in genes critical for RNA post-transcriptional modifications and protein ubiquitination as the two most
significant functional outcomes of OrfA expression. In these two groups, several subunits of the spliceosome, cellular splicing factors and family
members of the proteasome-ubiquitination systemwere identified. These findings provide novel information on the versatile function of OrfA during
FIV infection and indicate a fine-tuning mechanism of the cellular environment by OrfA to facilitate efficient FIV replication.
© 2007 Elsevier Inc. All rights reserved.Keywords: FIV; OrfA; Microarray; Spliceosome; Splicing factors; Proteasome; Ubiquitination; Affymetrix; IngenuityIntroduction
FIV is a lentivirus associated with an AIDS-like syndrome in
the domestic cat (Pedersen, 1993). Like HIV, FIV can be
transmitted via mucosal exposure, blood transfer, and vertically
via prenatal and post-natal routes (O'Neil et al., 1995, 1996;
Obert and Hoover, 2000; Pedersen et al., 1987; Rogers and
Hoover, 1998) and the primary target of infection is the CD4+ T-
cell. The overall genomic structure of FIV is markedly similar to
HIV, although there are important distinctions (Olmsted et al.,
1989; Phillips et al., 1990; Talbott et al., 1989). One such
distinction is the lack of the transactivator gene, tat, and the
presence of a short open reading frame termed OrfA. Trans-⁎ Corresponding author. Fax: +1 858 784 2750.
E-mail address: jelder@scripps.edu (J.H. Elder).
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doi:10.1016/j.virol.2007.09.039lation of an approximate nine kDa protein encoded by this
region occurs from a bicistronic mRNA that also encodes
downstream Rev (de Parseval and Elder, 1999). The genomic
location, size, and structural features of OrfA have many si-
milarities to HIV Tat as well as to the L domain of visna virus,
both of which demonstrate transactivating functions. In fact,
OrfA has been shown to facilitate a net increase in translation of
proteins whose expression is driven from the FIV long terminal
repeats (LTRs) (de Parseval and Elder, 1999; Sparger et al.,
1992; Waters et al., 1996). However, OrfA does not act via a
TAR element, as is the case with HIV-1 Tat, and promotes a net
increase in transcription/translation via mechanisms distinct
from that of other lentiviruses (Chatterji et al., 2002; Gemeniano
et al., 2003). Attempts to show direct interaction of OrfA with
the FIV LTR proved negative (Chatterji et al., 2002) and the
gene is dispensable for viruses adapted for propagation in
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and G355-5 cells (Phillips et al., 1990). However, OrfA is
required for productive infection of the primary in vivo target
cell, CD4+ T-cells (Waters et al., 1996). Stable feline T-cell lines
expressing OrfA can function in trans to complement an OrfA-
defective FIV (this study; Gemeniano et al., 2003). Fur-
thermore, cats inoculated with OrfA-mutated FIV clones had a
greatly reduced plasma viremia (Pistello et al., 2002). Evidence
has been presented that a 39-bp deletion in OrfA gives a 4-fold
decrease in viral mRNA expression and a moderate decrease in
Gag protein expression (Gemeniano et al., 2003). It has also
been reported that OrfA may have relatedness to HIV-1 Vpr and
is implicated in facilitating cell cycle arrest and virus release
from the cell (Gemeniano et al., 2003, 2004). Overall, these
findings suggest that OrfA may be a multi-functional protein,
which would certainly be in keeping with the need for
versatility, given the relatively small viral genome.
In the present report, we used genome array analysis to study
the consequence of OrfA on pleiotropic cellular gene expression
in T-cells. RNA was prepared from cells transduced with Mig-
R1 vector expressing either green fluorescent protein (GFP)
alone or both GFP and OrfA and analyzed by microarray
analysis, using Affymetrix HU 133 Plus 2.0 chips. The results
show many parallels with gene expression observed in HIV-
infected cells (van 't Wout et al., 2003), with a down-regulated
expression of factors reported to influence HIV-1 mRNA
splicing. Furthermore, expressions of genes encoding ubiquitin-
conjugating enzymes and proteasome subunits were identified
as down-regulated in the OrfA-expressing T-cells.
Results
Generation and characterization of OrfA-expressing T-cells
In order to better understand the function of OrfA during
FIV infection, we generated stable cell lines expressing GFP+/-
FIV-PPR OrfA (Chatterji et al., 2002). These clones (termedFig. 1. Confirmation of functional OrfA expression by FIV-34TF10 infection of tran
OrfA in 104-C1 cells (104-C1-GFP-OrfA) trans complements the OrfA-defective clon
express GFP alone or GFP together with the following OrfA variants, stop: truncated
OrfAwith a Cys at position 44. The transfected cells were infected with 34TF10 or 34
RTactivity assay at 14 days post-infection. Cells expressing OrfAwith a Trp or Cys at
low proliferation rate in 104-C1 cells unless OrfA-Trp or OrfA-Cys is expressed by104-C1-GFP and 104-C1-GFP-OrfA) were established in the
primary IL-2-dependent T-cell line, 104-C1. Flow cytometry
analysis confirmed the GFP expression in 104-C1-GFP and
104-C1-GFP-OrfA to be N95% (data not shown). To assay for
expression of functional OrfA, the cells were infected with
FIV-34TF10, a strain deficient in functional OrfA protein (Phil-
lips et al., 1990; Talbott et al., 1989). The presence of OrfA
complemented FIV-34TF10 in trans and rescued viral replica-
tion in 104-C1-GFP-OrfA cells (Fig. 1A). In cells lacking OrfA
(104-C1 and 104-C1-GFP), only background levels of reverse
transcriptase activity was detected in the culture supernatant. In
addition, gene expression of OrfA in 104-C1-GFP-OrfA cells,
but not in 104-C1-GFP cells, was confirmed by Q-PCR (data
not shown). The OrfA mutation at residue 44 in FIV-34TF10
changes the native Tryptophan (Trp) residue to a stop codon.
Repair of this mutation restores wild-type infectivity on PBMCs
and T-cell lines (Waters et al., 1996). Consistent with this
finding, transduced 104-C1 cells expressing truncated OrfA-
Stop failed to trans-complement FIV-34TF10 (Fig. 1B). An
additional third base mutation was generated by alteration of the
codon at residue 44 from Trp to Cys and the mutant OrfA-Cys
was engineered into 104-C1 cells and FIV-34TF10. Interest-
ingly, 104-C1-GFP-OrfA Cys was able to trans-complement the
OrfA-defective FIV (Fig. 1B, left). However, placing this mu-
tation in the context of FIV-34TF10 (termed 34TF10-Cys) did
not generate wild-type levels of viral replication (Fig. 1B, right)
until a back mutation to Trp appeared at approximately 16 days
of culture (data not shown). These findings indicate that Cys at
residue 44 is a less stable residue than Trp but that the latter
residue is not mandatory for OrfA function. Low-level viral
replication results in rapid reversion to Trp in the context of the
virus as opposed to the genetically static state of the OrfA
plasmid.
Further analyses of the stable 104-C1 clones revealed a
small reduction in proliferation rate of the OrfA-expressing
cells and in cells expressing only GFP (Fig. 2A). FIV-PPR
OrfA has been reported to induce cell cycle arrest in the G2sfected 104-C1 cells and reverse transcriptase activity assay. (A) Expression of
e FIV-34TF10 and rescues viral replication. (B) 104-C1 cells were transfected to
OrfA due to a stop codon at position 44; Trp: OrfAwith Trp at position 44; Cys:
TF10 with Cys at position 44 (34TF10-Cys) and analyzed for viral replication by
residue 44 can rescue proliferation of 34TF10. However, 34TF10-Cys has a very
the cell.
Fig. 2. Proliferation rate and cell cycle distribution. (A) OrfA expression does not significantly change cell proliferation rate. Cells were seeded at 105/ml and counted
after 24, 48, and 72 h using a hemocytometer. (B) 104-C1-GFP and 104-C1-GFP-OrfA cells exhibit similar cell cycle distribution. Cellular DNAwas stained with
propidium iodide, cell fluorescence was measured by flow cytometry, and discrimination of cells in G0/G1, S, and G2/M phases was performed using FlowJo software.
104-C1 arrested cells were exposed to aphidicolin and Hoechst 33342 in two subsequent overnight incubations.
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niano et al., 2004). Therefore, cell cycle analysis of the 104-C1
clones was performed by staining ethanol-fixed cells in a
propidium-RNase solution and analyzed for cell fluorescence
by flow cytometry. No change in cell cycle distribution was
detected due to PPR OrfA expression in the feline T-cell line
104-C1 relative to 104-C1-GFP cells (Fig. 2B) or in feline
CrFK cells (data not shown).
Microarray analysis of OrfA expressing cells
Total RNA from 104-C1-GFP and 104-C1-GFP-OrfA cells
was isolated and subjected to reverse transcription followed by
in vitro transcription to generate biotinylated anti-sense RNA
probes. The labeled cRNA probes were hybridized to Affy-
metrix HU133 Plus 2.0 microarray chips representing more than
47,000 genome-wide transcripts. Differentially regulated genes
were identified by ANOVA analysis and Rank Products method.Fig. 3. Analysis of microarray data. (A) Rank Products method and ANOVA analysis
identified by each method and in the overlapping data set. (B) Exploration of the fu
Ingenuity Pathway Analysis (left) and Ingenuity Canonical Pathway Analysis (right
pathway assigned to the data set is due to chance alone.The list of regulated genes was annotated using Affymetrix
NetAffx software. Changes in gene expression levels ranged
from 0.2- to 5.6-fold with a general trend toward down-regulated
expression levels. Among the genes regulated, the percentage of
genes down-regulated in OrfA+ cells were 74% and 57% for
genes identified by ANOVA statistical analysis and Rank Pro-
ducts method, respectively. By using these two statistical ana-
lyses, a total of 596 genes were identified of which 24% were
present in both assays, i.e., the overlapping data set (Fig. 3A).
The functional relevance of the differentially expressed genes
was explored by Ingenuity Pathway Analysis and Ingenuity
Canonical Pathway Analysis software. Analyses of all data sets,
i.e., ANOVA, Rank Products or genes overlapping both statis-
tical analyses, revealed expression changes in genes critical for
“RNA post-transcriptional modification” and “protein ubiquiti-
nation” as the two most statistically significant functional out-
comes of OrfA expression. The data presented in Fig. 3B are a
classification of the genes in the overlapping data set based onwere both performed on the microarray data set. Indicated is the number of genes
nctional relevance of the genes in the overlapping array data set was done with
). Data are presented as the probability that each indicated biological function/
Table 2
Post-transcriptional modification genes identified by Rank Product (RP) or
ANOVA statistical analysis—without genes involved in RNA splicing
Gene RP ANOVA Fold
change
Protein name
CDC2 x x 0.57 Cell division cycle 2
CDK7 x 0.55 Cyclin-dependent kinase 7
CPSF6 x 0.68 Cleavage and polyadenylation-specific
factor 6
DDX17 x 1.24 DEAD (Asp-Glu-Ala-Asp)
box polypeptide 17
GRSF1 x 0.65 G-rich RNA sequence binding factor 1
hnRNP D x x 0.56 Heterogeneous nuclear
ribonucleoprotein D
397M. Sundstrom et al. / Virology 371 (2008) 394–404their involvement in different biological processes. Forty percent
of the genes in these two groups were found present in both
statistical analyses, see Tables 1–3.
Gene expression of spliceosome subunits and cellular splicing
factors are modulated by OrfA
In the RNA post-transcriptional modification group, a
predominant portion (64%) of the identified genes are involved
in the RNA splicing process (Table 1). Genes for RNA splicing
proteins that were differentially regulated in OrfA-expressing
cells include heterogeneous nuclear ribonucleoprotein (hnRNP)hnRNP DL x x 0.47 Heterogeneous nuclear
ribonucleoprotein D-like
KHDRBS1 x 0.80 KH domain containing, RNA binding,
signal transduction associated 1
NUDT21 x 0.65 Nudix (nucleoside diphosphate linked
moiety X)-type motif 21
PABPN1 x x 0.65 Poly(A) binding protein, nuclear 1
PAPOLG x 0.83 Poly(A) polymerase gamma
PCBP1 x 0.71 Poly(rC) binding protein 1
RBPMS x 1.47 RNA binding protein with multiple
splicing
RNGTT x x 0.60 RNA guanylyltransferase and
5′-phosphatase
Table 1
Post-transcriptional modification genes identified by Rank Product (RP) or
ANOVA statistical analysis—RNA splicing genes
Gene RP ANOVA Fold
change
Protein name
CSTF3 x x 0.46 Cleavage stimulation factor,
3′ pre-RNA, subunit 3
CUGBP1 x x 0.55 CUG triplet repeat, RNA binding
protein 1
FUSIP1 x 0.62 FUS interacting protein
(serine/arginine-rich) 1
hnRNP A x 0.86 Heterogeneous nuclear
ribonucleoprotein A1 (A)
hnRNP A2B1 x x 0.64 Heterogeneous nuclear
ribonucleoprotein A2/B1
hnRNP H x 0.71 Heterogeneous nuclear
ribonucleoprotein H1 (H)
hnRNP H3 x x 0.72 Heterogeneous nuclear
ribonucleoprotein H3 (2H9)
hnRNP Q x x 0.63 Heterogeneous nuclear
ribonucleoprotein Q, SYNCRIP
MBNL1 x 0.54 Muscleblind-like (Drosophila)
NCBP1 x x 0.67 Nuclear cap binding protein subunit 1
PLRG1 x 0.82 Pleiotropic regulator 1
(PRL1 homolog, Arabidopsis)
PPIG x 0.64 Peptidylprolyl isomerase G
(cyclophilin G)
PTBP2 x 0.85 Polypyrimidine tract binding
protein 2
RP9 x 0.64 Retinitis pigmentosa 9
(autosomal dominant)
SFRS1 x 0.66 Splicing factor, arginine/serine-rich 1
(splicing factor 2), ASF/SF2
SFRS3 x x 0.67 Splicing factor, arginine/serine-rich 3,
SRP20
SFRS7 x x 0.56 Splicing factor, arginine/
serine-rich 7, 9G8
SFRS15 x 0.66 Splicing factor, arginine/serine-rich 15
SNRPA x x 0.62 Small nuclear ribonucleoprotein
polypeptide A
SNRPA1 x x 0.52 Small nuclear ribonucleoprotein
polypeptide A′
SNRPB x x 0.70 Small nuclear ribonucleoprotein
polypeptides B and B1
TRA2A x 1.24 Transformer-2 alpha
U2AF35 x 0.67 U2 small nuclear RNA auxiliary
factor 1, U2AF1
UAP56 x x 0.69 U2AF65-associated protein 1,
56-kDa, BAT1
WBP11 x 0.55 WW domain binding protein 11family members, serine/arginine-rich (SR) splicing factors and
subunits of the spliceosome machinery including small nuclear
ribonucleoprotein polypeptides (SNRPs; see Table 1). Retro-
viruses utilize alternative splicing to generate expression of
several gene products from one primary polycistronic transcript
(Purcell and Martin, 1993). This splicing process makes use of
suboptimal splice sites and cis-acting elements in the viral
genome. The cis-acting elements act mainly by binding hnRNP
family members and SR splicing factors. In OrfA-expressing
cells, the following hnRNPs exhibited down-regulated expres-
sion; hnRNP A, hnRNP A2B1, hnRNP H, hnRNP H3, and
hnRNP Q (Table 1). Furthermore, the array data analysis re-
vealed an OrfA-initiated down-regulation of four SR splicing
factors, namely, SFRS1 (ASF/SF2), SFRS3 (SRp20), SFRS7
(9G8), and SFRS15 (Table 1). Most interestingly, the majority
of the hnRNP and SR family members identified here have also
been reported to influence HIV-1 mRNA splicing (Caputi et al.,
1999; Domsic et al., 2003; Jacquenet et al., 2001; Ropers et al.,
2004; Stoltzfus and Madsen, 2006; Tange et al., 2001; Zahler
et al., 2004).
The actual splicing reaction is performed by the spliceosome,
which consists of the U1, U2, U4, U5, and U6 small nuclear
ribonucleoproteins (snRNPs) (Graveley, 2000). The expression
of the following SNRP genes were found modulated by OrfA
(Table 1); SNRPA—a subunit specific of U1 snRNP (Sillekens
et al., 1987); SNRPA1—a component specific of U2 snRNP
(Sillekens et al., 1989); and SNRPB—a subunit shared by all
snRNPs (Luhrmann et al., 1990).
U2 auxiliary factor (U2AF) is a heterodimer of U2AF35 and
U2AF65 proteins and has a role in the first step of spliceosome
assembly by binding the 3′ splice site (Graveley, 2000). Our array
Table 3
Protein ubiquitination pathway genes identified by Rank Product (RP) or ANOVA
statistical analysis
Gene RP ANOVA Fold
change
Protein name
ANAPC5 x 0.60 Anaphase promoting complex subunit 5
CDC20 x 0.52 CDC20 cell division cycle 20 homolog
(S. cerevisiae)
HSPA8 x 0.55 Heat shock 70 kDa protein 8
PSMA1 x x 0.66 Proteasome subunit, alpha type, 1
PSMA2 x 0.63 Proteasome subunit, alpha type, 2
PSMA5 x x 0.68 Proteasome subunit, alpha type, 5
PSMA7 x x 0.63 Proteasome subunit, alpha type, 7
PSMB7 x 0.81 Proteasome subunit, beta type, 7
PSMC6 x x 0.62 Proteasome 26S subunit, ATPase, 6
PSMD1 x 0.56 Proteasome 26S subunit, non-ATPase, 1
PSMD8 x 0.75 Proteasome 26S subunit, non-ATPase, 8
PSME2 x x 0.63 Proteasome activator subunit 2
(PA28 beta)
PSME3 x 0.69 Proteasome activator subunit 3
(PA28 gamma)
SKP1A x 0.67 S-phase kinase-associated protein 1A
(p19A)
TAP2 x x 1.23 Transporter 2, ATP-binding cassette,
sub-family B (MDR/TAP)
TCEB1 x x 0.61 Transcription elongation factor B (SIII)
UBE2C x x 0.43 Ubiquitin-conjugating enzyme E2C
UBE2D2 x 0.72 Ubiquitin-conjugating enzyme E2D 2
(UBC4/5 homolog, yeast)
UBE2L3 x 0.67 Ubiquitin-conjugating enzyme E2L 3
UBE2N x x 0.60 Ubiquitin-conjugating enzyme E2N
(UBC13 homolog, yeast)
UBE2V1 x 0.60 Ubiquitin-conjugating enzyme E2 variant 1
UBE3A x 0.78 Ubiquitin protein ligase E3A
(HPV E6-associated protein)
USP1 x x 0.61 Ubiquitin-specific peptidase 1
USP6 x 1.35 Ubiquitin-specific peptidase 6
(Tre-2 oncogene)
USP24 x 1.12 Ubiquitin-specific peptidase 24
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cells. UAP56 (U2AF65-associated protein), an essential splicing
factor required for U2 snRNP binding to pre-mRNA branch site
(Fleckner et al., 1997), is also down-regulated by OrfA (Table 1).
Among the other genes identified as coding for RNA post-
transcriptional modification proteins (Table 2) were some of
specific relevance for retroviral replication. The mammalian
mRNA capping enzyme RNA guanylyltransferase and 5′-phos-
phatase (RNGTT or Mce1) has been reported to both interact
with and to be regulated by HIV-1 Tat (Chiu et al., 2001).
CDK7 (Cyclin-dependent kinase 7) has been implicated in
general HIV-1 transcription (Kim et al., 2006) as well as Tat-
mediated transcription (Nekhai et al., 2002). KHDRBS1 (KH
domain containing, RNA binding, signal transduction associ-
ated 1 or SAM68) plays a role in Rev-mediated RNA export
(Modem et al., 2005) and HIV-1 RNA polyadenylation (Mc-
Laren et al., 2004). According to the Ingenuity database, the
following genes identified as regulated in the array can be
classified as being involved in theRNApolyadenylation process;
CPSF6, GRSF1, NUDT21, PABPN1, PAPOLG, and SNRPA
(Tables 1 and 2).Modulation of RNA expression for genes in the
ubiquitin–proteasome pathway
In addition to genes in the RNA post-transcriptional modi-
fication group, several genes involved in the process of protein
ubiquitination and degradation were differentially regulated in
the OrfA expressing T-cells. Protein degradation through the
ubiquitin–proteasome pathway plays an important role in im-
mune and inflammatory responses. There are two distinct steps
in this pathway; conjugation of ubiquitin molecules to the target
protein and degradation of the ubiquitinated protein by the 26S
proteasome (Glickman and Ciechanover, 2002). Expression of
five different E2 ubiquitin-conjugating enzymes and one E3
ubiquitin–protein ligase were down-regulated by OrfA expres-
sion (Table 3). Furthermore, three different ubiquitin-specific
peptidases (USPs) were also regulated in OrfA-expressing cells
(Table 3). USPs belongs to the family of de-ubiquitinating
enzymes that can release ubiquitin from degraded proteins or
de-ubiquitinylate proteins prior to their association with the
proteasome (Glickman and Ciechanover, 2002).
The peptide cleavage of ubiquitinated proteins takes place in
the 26S proteasome, which is a multicatalytic proteinase com-
plex consisting of a 20S catalytic core and two 19S regulatory
complexes responsible for recognition, binding and unfolding
of ubiquitinated proteins (Kloetzel and Ossendorp, 2004).
Eight different subunits of the proteasome were down-regu-
lated in OrfA-expressing cells (Table 3). These are four 20S
core alpha subunits (PSMA1, 2, 5 and 7); one 20S core beta
subunit (PSMB7); and three 19S subunits (PSMC6, PSMD1
and PSMD8). Proteasome inhibitors have been reported to
enhance HIV-1 infectivity 4- to 26-fold (Wei et al., 2005), thus
suggesting a cellular defense system with proteasome-mediated
degradation of viral particles or proteins. Furthermore, HIV-1
Tat and Nef can impair proteasome activity (Apcher et al.,
2003; Qi and Aiken, 2007), as a mechanism to protect viral
particles from degradation (Qi and Aiken, 2007).
Interferon-gamma (IFN-γ) can change the 26S proteasome
into an immunoproteasome responsible for generation of pep-
tides for MHC class-I presentation. This is achieved by an IFN-γ
induced up-regulation of both specific proteasome subunits and
the immunoproteasome regulator, PA28/11S. Interestingly, in
our array analysis two PA28 subunits, i.e., PSME2 and PSME3
are down-regulated in OrfA expressing cells (Table 3). Similarly,
HIV-1 Tat can modulate the expression of subunits specific for
the immunoproteasome (Gavioli et al., 2004; Remoli et al.,
2006) and interferes with the formation of the immunoprotea-
some, which leads to reduced antigen presentation (Huang et al.,
2002; Seeger et al., 1997).
Another interesting gene identified as being regulated in
OrfA expressing cells is HMGB1 (High mobility group B1) that
belongs to the HMG protein family of abundant non-histone
components of chromatin. HMGB1, which was down-regulated
by OrfA (data not shown), is released by activated macro-
phages/monocytes and can stimulate production of chemokines
and induce a down-regulation of viral replication in primary
HIV-1-infected monocyte-derived macrophages (Nowak et al.,
2006; Wang et al., 2006). HMGB1 has also been reported to
Fig. 4. Q-PCR validation of microarray data. Fold difference of RNA levels of genes identified in the microarray analysis (grey bars) were analyzed in 104-C1-GFP
and 104-C1-GFP-OrfA cells by Q-PCR (white bars). (A) RNA fold differences for four genes identified as highly regulated by OrfA. (B) RNA fold differences for five
regulated genes of the splice factor and proteasome families.
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epithelial cells (Naghavi et al., 2003).
Validation of microarray data by Quantitative Real-Time PCR
(Q-PCR)
Q-PCR is the most appropriate tool for confirmation of
gene expression results obtained from microarray analysis. As
an independent measure of the influence of OrfA on gene
expression in 104-C1 T-cells, we performed Q-PCR using
primer sets corresponding to a sampling of genes identified as
OrfA-responsive in the microarray analysis (Fig. 4). Primers
were designed for four highly OrfA-responsive genes and the
mRNA levels were analyzed in 104-C1-GFP and 104-C1-
GFP-OrfA cells (Fig. 4A). In addition, mRNA levels of five
regulated genes of the splice factor and proteasome families
shown in Tables 1 and 3 were also analyzed (Fig. 4B). Of the
nine genes analyzed by Q-PCR, eight yielded trends virtually
identical to results noted in the microarray analysis (Fig. 4).
One gene, PSMA7, which showed a slight downturn in
expression by microarray, was essentially unchanged in the Q-
PCR analysis. Thus, the two types of gene expression analysis
showed high agreement, lending support to the relevance of
the array data.
Discussion
In order to better understand the function of OrfA during FIV
infection and replication, we generated stable cell lines ex-
pressing either GFP alone or both GFP and OrfA. As reported
previously (Chatterji et al., 2002), expression levels for OrfA in
FIV-infected cells is extremely low and is essentially undetect-
able by either radioimmune precipitation or Western blotting
techniques. Likewise, net expression of OrfA in the stable cell
line used in the present study is low, although in vitro trans-
cription/translation readily demonstrated OrfA expression from
the vector construct used to create the cell line (Chatterji et al.,
2002), data not shown. The implication from these findings is
that the protein has a limited half-life in both FIV-infected cells
and in the stable 104-C1-GFP-OrfA cell line. Important to thevirological relevance of the present study, OrfA in the context of
the stable cell line was able to rescue OrfA-defective FIV-
34TF10 in trans (Fig. 1A) as well as enhance FIV LTR-driven
transcription/translation (data not shown). We previously noted
cell toxicity with other OrfA-expressing cell lines and surmise
that higher levels of expression result in cell toxicity. Thus, we
feel that the cell line used here is the most appropriate for
reaching conclusions regarding the mandatory role of OrfA in
FIV replication in T-cells. Further analyses of the stable cell
lines revealed a minor down-regulation in the proliferation rate
of the OrfA expressing cells (Fig. 2A) but there were no changes
in cell cycle distribution due to OrfA expression in the primary
T-cell line 104-C1, compared to 104-C1-GFP (Fig. 2B), or in
CrFK cells (data not shown). These cell cycle observations in
FIV relevant feline cells diverge from what previously has been
reported when expressing OrfA in primate COS-7 cells and thus
may be connected to interspecies differences or due to relative
expression levels of OrfA in the two studies.
The impact of OrfA on the pleiotropic gene expression
pattern in feline T-cells was characterized bymicroarray analysis
using RNA from the 104-C1-GFP and 104-C1-GFP-OrfA cells.
Since no feline chips are available, we compared the relative
reactivity of feline RNA to both murine and human chips and
settled on use of the human HU133Plus 2.0 chip for these
studies. Although it is unlikely that we could expect complete
cross-species hybridization with this chip, we felt it appropriate
to use the available technology with the knowledge that positive
findings could be independently verified and pursued.
By using ANOVA analysis and Rank Products method,
approximately 600 genes were identified as differentially ex-
pressed in the stable clones. The changes in expression levels are
subtle for the predominant portion of the genes. This is consistent
with the idea of a virus-induced modification of the cellular
environment, without fully overtaking or killing the host cell, at
least in the short term.Althoughmany changes in expression level
were small, families of genes were regulated in the same direction
and these changes may pave the way for a downstream functional
outcome relevant to virus replication. The functional relevance of
the gene expression changes was explored by Ingenuity Pathway
Analysis. For all data sets (ANOVA, Rank Products, or genes
400 M. Sundstrom et al. / Virology 371 (2008) 394–404present in both assays), “RNA post-transcriptional modification”
and “protein ubiquitination” were revealed as the two most
important functional outcomes of OrfA expression (Fig. 3B).
HIV-1, FIV, and other retroviruses utilize alternative splicing
to generate expression of several gene products from one pri-
mary polycistronic transcript while at the same time controlling
the level of splicing to allow generation of full-length genomic
RNA for packaging in new viral particles. The alternative
splicing process is dependent on suboptimal splice sites and cis-
acting elements in the viral genome. The cis-acting elements
include exonic splicing silencers (ESS) and intron splicing
silencers (ISS) that are regulated by hnRNP A/B family mem-
bers or by hnRNP H. Another group of cis-acting elements are
exonic splicing enhancers (ESE) that function by binding
members of the SR protein family (Graveley, 2000). For a
review of ESS, ISS, and ESE function in HIV-1 RNA splicing,
see Kammler et al. (2006).
Among the splicing genes found down-regulated by OrfA
are hnRNP A, hnRNP A2B1, and hnRNP H (Table 1). Expres-
sion of these three genes have previously been described down-
regulated, at a similar level, after HIV-1 infection of a human
CD4+ T cell line (van 't Wout et al., 2003) and hnRNPA is also
down-regulated in astrocytes expressing HIV-1 Tat (Pocernich
et al., 2005). Furthermore, hnRNP A/B proteins and hnRNP H
have been described as splicing inhibitors of HIV-1 RNA (Ca-
puti et al., 1999; Jacquenet et al., 2001; Stoltzfus and Madsen,
2006). hnRNP H3 and hnRNP Q (SYNCRIP) are two other
hnRNP splicing proteins identified as down-regulated in OrfA
expressing cells (Table 1). Of these proteins, hnRNP H3 is
known to bind HIV Env RNA (Caputi et al., 1999).
SR splicing factors have several functions in splicing of
precursor mRNA and are required both for selection of alterna-
tive splice sites and for removal of constitutively spliced introns.
In the array data set, the OrfA expressing T-cells displayed a
down-regulation of four SR splicing factors, namely, SFRS1
(ASF/SF2), SFRS3 (SRp20), SFRS7 (9G8), and SFRS15. Ana-
logous to our study, three of these SR splicing factors (ASF/
SF2, SFRS3, and 9G8) have been reported down-regulated to
the same extent in earlier studies using HIV-1-infected T-cells
(Ryo et al., 2000; van 't Wout et al., 2003). ASF/SF2 and 9G8
have been identified as factors that influence the splicing pattern
of HIV-1 pre-mRNA (Caputi et al., 1999; Domsic et al., 2003;
Ropers et al., 2004; Tange et al., 2001; Zahler et al., 2004) and
an altered expression of these genes/proteins have a prominent
effect on HIV-1 protein expression and virion production (Jac-
quenet et al., 2001; Ropers et al., 2004; Wang et al., 1998). In
our array data set, three SNRP subunits of the spliceosome were
also identified as modulated by the presence of OrfA (Table 1).
The HIV accessory gene product Vpr has been reported to
influence splicing of viral RNA and has a differential effect on
the level of spliced viral RNA in integrase-defective HIV (Poon
et al., 2007). Vpr has also been shown to interact with the
spliceosomal protein SAP145 and thereby mediate inhibition of
cellular precursor mRNA splicing and induction of G2 arrest
(Hashizume et al., 2007; Terada and Yasuda, 2006). These
findings are consistent with parallels drawn by Gemeniano et al.
(2004) between HIV-1 Vpr and FIV OrfA.Ubiquitin–proteasome degradation of proteins plays an
important role in a variety of basic cellular processes as well
as in immune and inflammatory responses. Proteins are directed
to degradation by conjugation of ubiquitin molecules. The
degradation of the ubiquitinated protein is accomplished by the
26S proteasome (Glickman and Ciechanover, 2002). Three
types of enzymes are needed for the ubiquitination process, i.e.,
E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating en-
zyme, and E3 ubiquitin–protein ligase. The role of E1 is to
activate ubiquitin molecules, which are then transferred to the
protein substrate by E2. Finally, conjugation of ubiquitin to the
protein is performed by E3 by binding of both E2 and the
protein substrate (Glickman and Ciechanover, 2002). The ubi-
quitin system has a hierarchical structure where E1 interacts
with all E2s, each type of E2 can interact with many different
E3s and each E3 targets several substrates. In our array data set,
several E2 ubiquitin-conjugating enzymes and one ubiquitin–
protein ligase exhibited a down-regulated gene expression
induced by OrfA (Table 3). Thus, one way OrfA may facilitate
viral replication is by limiting ubiquitination/degradation of
viral proteins in the host cell.
The immunosuppressive activity of HIV-1 Tat (Viscidi et al.,
1989) can partly be explained by alteration of immunoprotea-
some activity. Tat inhibits the activity of 20S and competes with
PA28/11S for binding to 20S. Therefore, formation of the im-
munoproteasome is blocked and presentation of antigenic
peptides is reduced (Huang et al., 2002; Seeger et al., 1997).
Additionally, Tat can modulate the expression of specific sub-
units of the immunoproteasome and thereby change the peptide
antigen profile of cells expressing or being exposed to Tat
(Gavioli et al., 2004; Remoli et al., 2006). In this study, we
identified a down-regulation by OrfA of two PA28 subunits
(PSME2 and PSME3). This finding is consistent with an ad-
ditional role of OrfA in deregulation of antigen presentation
during FIV infection.
Furthermore, eight genes encoding general proteasome sub-
units are down-regulated in OrfA expressing cells (Table 3).
Similarly, HIV-1 Tat has also been shown to alter the activity of
the proteasome. Among the proteasome subunits that interact
with Tat is PSMA7 (Apcher et al., 2003), a protein also identi-
fied in our microarray analysis as down-regulated by OrfA.
Another HIV-1 accessory factor, Nef, has recently been impli-
cated in protection of HIV-1 particles from proteasomal de-
gradation (Qi and Aiken, 2007), and HIV Vpr-mediated G2
arrest has been reported to be dependent on interaction of Vpr
with ubiquitin–ligase components (Wen et al., 2007). However,
the action of Vpr here most likely promotes proteasomal de-
gradation of a cellular factor (Wen et al., 2007). Additionally,
recent studies suggest that one phase of rhesus TRIM5α re-
striction of HIV-1 infection is accomplished by blockage of late
reverse transcriptase product formation via proteasome activity
(Wu et al., 2006).
The down-regulation of ubiquitin conjugating enzymes and
proteasome subunits byOrfA imply a defense system initiated by
FIV to avoid proteasome-mediated degradation of either cellular
proteins facilitating efficient FIV replication or of FIV viral
proteins/particles. Thus, the down-regulation of components in
401M. Sundstrom et al. / Virology 371 (2008) 394–404the ubiquitin–proteasome pathway may help explain the finding
that OrfA is required for efficient FIV particle formation (Geme-
niano et al., 2003).
The present study suggests that OrfA mediates a fine-tuning
of the cellular splicing and protein degradation machinery and
thus gives insight into the mechanism that makes OrfA critical
for efficient FIV replication in lymphocytes.
Materials and methods
Cell lines and virus
The primary IL-2-dependent T-cell line 104-C1 was isolated
from feline PBMCs by limiting dilution (Lerner et al., 1998)
and generously provided by Dr. Chris Grant (Custom Mono-
clonals Int., W. Sacramento, CA). 104-C1 cells were main-
tained in RPMI 1640 (Gibco, Carlsbad, CA) supplemented
with 10% fetal bovine serum (Atlanta Biologicals, Lawrence-
ville, GA), 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate
(Gibco), 10 mM HEPES buffer (Gibco), 1× minimal essential
medium-vitamins (Cellgro Mediatech, Herndon, VA), 1× non-
essential amino acids (Gibco), 1× β-mercaptoethanol (Gibco),
2.5 μg/ml concanavalin A (Sigma, St. Louis, MO), 50 U/ml of
human recombinant IL-2 (gift from Hoffman-La Roche), and
50 μg/ml gentamycin (Gemini Bioproducts, West Sacramento,
CA).
Construction of 104-C1 cells expressing GFP (104-C1-GFP)
or co-expressing GFP and FIV-PPR (Phillips et al., 1990) OrfA
(104-C1-GFP-OrfA) has been described previously (Chatterji
et al., 2002). Briefly, GP2-293 packaging cells (Clontech, Palo
Alto, CA) were transiently transfected with pVSV-G and Mig
R1 (Pear et al., 1998) or Mig R1-OrfA to produce a retroviral
stock, which was used to transduce 104-C1 cells by spinocula-
tion. GFP-expressing cells were sorted with a FACS Vantage SE
I (Becton Dickinson, Franklin Lakes, NJ) at the TSRI Flow
Cytometry Core Facility. GFP+ cells were scaled up and sorted a
second time followed by confirmation of GFP expression by
flow cytometric analysis. OrfA expression in 104-C1-GFP-
OrfA was confirmed by 35S-labeling followed by immunopre-
cipitation and has been described previously (Chatterji et al.,
2002).
FIV-34TF10, a cell line-adapted FIV strain derived from the
Petaluma isolate (Talbott et al., 1989), was used as an OrfA-
defective strain for trans-complementation assays.
Micro-reverse transcriptase (RT) activity assay
Micro-RT activity assay was performed as previously de-
scribed (de Parseval and Elder, 2001; de Parseval et al., 1997).
Briefly, primary and transfected 104-C1 cells were infected with
FIV-34TF10, which lacks functional OrfA expression, or with
mutants of 34TF10 in which the stop codon in OrfA was
replaced with the codon for Cysteine (Cys), rendering the gene
functional. Virus production was monitored by analysis of RT
activity. Fifty microliters of cell-free supernatant was incubated
10 min at room temperature with 10 μl of lysis buffer (0.75 M
KCl, 20 mM dithiothreitol, 0.5% Triton X-100). Forty micro-liters of a mixture containing 125 mM Tris–HCl (pH 8.1),
12.5 mM MgCl2, 1.25 μg poly(rA)-poly(dT)12–18 (Amersham
Biosciences, Piscataway, NJ), and 1.25 μCi of [3H]dTTP (Du-
Pont, Boston, MA) was added to the sample followed by 2 h
incubation at 37°C. RT activity was measured as previously
described (de Parseval et al., 1997).
Proliferation assay
Growth rates of control and transfected cells weremeasured in
order to assess the influence of recombinant protein expression.
Control 104-C1, 104-C1-GFP, and 104-C1-GFP-OrfA cells were
seeded at 105 cells per well, in triplicate. Cells were then counted
after 24, 48, and 72 h using a hemocytometer.
Cell cycle analysis
104-C1, 104-C1-GFP, and 104-C1-GFP-OrfA cells were
harvested and resuspended in 0.5 ml phosphate-buffered saline
(PBS) to achieve a single cell suspension at 2×106 cells/ml.
Cells were fixed in 70% ethanol for 2 h before being washed in
PBS and suspended in Propidium Iodide (PI)/Triton X-100
staining solution containing 0.1% (v/v) Triton X-100 (Kodak,
Rochester, NY), 0.2 mg/ml DNase-free RNase A (Sigma), and
0.02 mg/ml PI (Sigma) for 30 min at room temperature. Cell
fluorescence was measured by flow cytometry and analyzed
according to Basic protocol 1 in Current Protocols in Cytometry
(Darzynkiewicz and Juan, 1997). Discrimination of cells in G0/
G1, S, and G2/M phases of the cell cycle was performed using
FlowJo 4.6 software. As a control, 104-C1 cells were arrested at
G2/M phase by overnight incubation with 4 μg/ml Aphidicolin
(Fisher, Pittsburgh, PA) followed by another overnight incu-
bation in 0.1 μg/ml Hoechst 33342 (Promega, Madison, WI).
Arrested cells were stained and analyzed as above.
RNA isolation
Total RNA for quantitative real-time PCR and microarray
assays was isolated from 2.5×106 104-C1-GFP or 104-C1-GFP-
OrfA cells using TRIZOL Reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer's protocol.
The GeneChip Human Genome U133 Plus 2.0 Array
As no feline microarray is yet available, labeled RNA (see
below) originating from the transfected 104-C1 cells, was
hybridized to the commercially available Affymetrix Gene-
Chip oligonucleotide arrays Human Genome U133 Plus 2.0
(HU133Plus 2.0) and Mouse 430 2.0 (Affymetrix, Santa Clara,
CA). As the human array gave a higher number of present
transcripts in this cross-species analysis (9.7% compared to
8.3% for the mouse array), the HU133Plus 2.0 array was used
throughout this study. The HU133Plus 2.0 oligonucleotide
array has a total of 54,675 probe sets representing over 47,000
transcripts. A complete description and annotation for the
HU133Plus 2.0 array is available at http://www.affymetrix.
com/products/arrays/specific/hgu133plus.affx.
402 M. Sundstrom et al. / Virology 371 (2008) 394–404Microarray RNA processing, labeling, and chip hybridization
Labeled cRNA probes were generated from total RNA
samples using theMessageAmp II-BiotinEnhancedKit (Ambion
Inc., Austin, TX). Briefly, 500 ng of total RNA was reverse
transcribed with a T7 oligo(dT) primer bearing a T7 promoter
sequence followed by in vitro transcription of the resulting DNA
with T7 RNA polymerase to generate anti-sense RNA copies of
each mRNA. Biotinylated cRNA probes were hybridized to
Human Genome U133 Plus 2.0 arrays using the Hybridization
Oven 640 according to the manufacturer's standard protocol.
Arrays were processed using the Affymetrix Fluidics Station 450
and scanned using the ScanArray 3000with default settings and a
target intensity of 250 for image scaling (Affymetrix).
Microarray data analysis
Diagnostic plots showing distribution of raw signals and
RNA degradation profiles of all probe sets from 5′ to 3′ posi-
tions were used to eliminate outlier chips. One chip was ex-
cluded from the study due to outlying distribution and RNA
degradation slope. Robust Multichip Average normalization
was applied on the data followed by adjustment of the data for
batch effects using an empirical Bayes framework (Johnson
et al., 2007). Subsequently, both the Rank Products method
(Breitling et al., 2004) and ANOVA analysis were performed
using BRB Array tools (Radmacher et al., 2002) to discover
differential gene expression. Differentially expressed genes
were identified from the Rank Products method at 10% false-
positive rate and from the ANOVA analysis at a univariate
p-value level of 0.001. The list of regulated genes was an-
notated using the Affymetrix NetAffx Web site (http://www.
affymetrix.com/analysis/index.affx). Microarray processing,
data analysis, and classification of genes were performed at
the TSRI DNA Array Core Facility, La Jolla, CA.
Classification and functional analyses of genes
Ingenuity Pathways Knowledge Base, a knowledge bank of
biological findings for human, mouse, and rat genes (Ingenu-
ity® Systems, http://www.ingenuity.com/) was used for classi-
fication of the differentially expressed genes based on their
involvement in biological processes. The functional analyses of
the genes were generated through the use of Ingenuity Pathways
Analysis (Ingenuity® Systems) and used to identify the biolo-
gical functions that were most significant to the array data set.
Ingenuity Canonical Pathways Analysis was also used to iden-
tify the pathways from the Ingenuity analysis library of canoni-
cal pathways that were most significant to the data set. Fischer's
exact test was used to calculate p-values determining the pro-
bability that each biological function/canonical pathway as-
signed to that data set is due to chance alone.
cDNA synthesis
Residual genomic DNAwas removed from the total RNA by
the Turbo DNA-free kit (Ambion). One microgram of total RNAwas reverse transcribed using Transcriptor First Strand cDNA
synthesis kit and random hexamer primers according to manu-
facturer's instructions (RocheApplied Science, Indianapolis, IN).
Q-PCR
For each reaction, 1 μl of a 1:10 dilution of cDNA, 11.25 μl
of dH2O, 12.5 μl of SYBR Green PCR master mix (Qiagen,
Valencia, CA), and 500 nM of each forward and reverse primers
(see below) were mixed in 25 μl of total volume. Quantitative
Real-time PCR (Q-PCR) was performed using an ABI PRISM
7700 Sequence Detector (Perkin Elmer, Waltham, MA) and the
following conditions: 50 °C, 2 min and 95 °C, 10 min, followed
by 45 cycles of 95 °C, 15 s, and 60 °C, 1 min. The deltadelta
crossing thresholds (Ct) method was used for data analysis
(according to the Applied Biosystems manual). For each primer
set, gene expression levels were quantified relative to that of
18S rRNA. Confirmation of single amplicons, and lack of
primer–dimer formation, was performed by melting-curve ana-
lysis and agarose gel electrophoresis.
Q-PCR primers
Primers for the following feline genes were used for Q-
PCR quantification analyses, 18S; fibrillin 1 (FBN1); plexcin
C1 (PLXCN1); early B cell factor (EBF), heterogeneous nu-
clear ribonucleoprotein D-like (hnRNP DL), UAP56, hnRNP





















Nucleotide sequences for the feline genes were identified by
cross-species megaBLAST analysis in which the sequence for
the human gene was compared with the 2× sequence assembly of
the domestic cat genome from The Broad Institute and Agen-
court Bioscience Corporation. Primers were designed using
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi; Rozen and Skaletsky, 2000).
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